Global Oral GLP-1 麻豆原创 Research Report 2023

Publication ID:

PB501242274

Publication Date:

January 2, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Oral GLP-1 market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
The main driving factors for oral GLP-1 receptor agonists are the following:
麻豆原创 demand: As the number of diabetic patients continues to increase around the world, the demand for diabetes treatment drugs is also growing. As a new type of hypoglycemic drug, oral GLP-1 receptor agonists have high efficacy and good safety, so the market demand is also increasing.
Scientific and technological innovation: With the continuous development of biotechnology, scientists have continued to conduct in-depth research on GLP-1 receptor agonists, and have a deeper understanding of their mechanism of action and pharmacological effects. This provides technical support for the development of oral GLP-1 receptor agonists and promotes the development of this field.
Policy support: Government support and encouragement policies for the pharmaceutical industry provide a good environment for the development and marketing of oral GLP-1 receptor agonists. For example, agencies such as the U.S. Food and Drug Administration (FDA) have provided a fast track for the approval of innovative drugs, accelerating the marketing process of oral GLP-1 receptor agonists.
Capital investment: The research and development of oral GLP-1 receptor agonists requires substantial financial support, including clinical trials, production and marketing. Large pharmaceutical companies and venture capital institutions are increasingly investing in the field of oral GLP-1 receptor agonists, providing funding for the development of this field.
Clinical needs: Traditional diabetes treatment drugs have some side effects and limitations. As a new type of hypoglycemic drug, oral GLP-1 receptor agonists have better tolerance and lower side effects and can meet clinical needs. , improve the treatment effect and quality of life of patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Oral GLP-1 market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Eli Lilly
Novo Nordisk
Pfizer
AstraZeneca
Sanofi
Segment by Type
Sitagliptin
Saxagliptin
Alagliptin
Others
Segment by Application
Diabetics
Weight Loss People
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Oral GLP-1 report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Oral GLP-1 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Sitagliptin
1.2.3 Saxagliptin
1.2.4 Alagliptin
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global Oral GLP-1 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Diabetics
1.3.3 Weight Loss People
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oral GLP-1 麻豆原创 Perspective (2018-2029)
2.2 Oral GLP-1 Growth Trends by Region
2.2.1 Global Oral GLP-1 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Oral GLP-1 Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Oral GLP-1 Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Oral GLP-1 麻豆原创 Dynamics
2.3.1 Oral GLP-1 Industry Trends
2.3.2 Oral GLP-1 麻豆原创 Drivers
2.3.3 Oral GLP-1 麻豆原创 Challenges
2.3.4 Oral GLP-1 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oral GLP-1 Players by Revenue
3.1.1 Global Top Oral GLP-1 Players by Revenue (2018-2023)
3.1.2 Global Oral GLP-1 Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Oral GLP-1 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oral GLP-1 Revenue
3.4 Global Oral GLP-1 麻豆原创 Concentration Ratio
3.4.1 Global Oral GLP-1 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oral GLP-1 Revenue in 2022
3.5 Oral GLP-1 Key Players Head office and Area Served
3.6 Key Players Oral GLP-1 Product Solution and Service
3.7 Date of Enter into Oral GLP-1 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Oral GLP-1 Breakdown Data by Type
4.1 Global Oral GLP-1 Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Oral GLP-1 Forecasted 麻豆原创 Size by Type (2024-2029)
5 Oral GLP-1 Breakdown Data by Application
5.1 Global Oral GLP-1 Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Oral GLP-1 Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Oral GLP-1 麻豆原创 Size (2018-2029)
6.2 North America Oral GLP-1 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Oral GLP-1 麻豆原创 Size by Country (2018-2023)
6.4 North America Oral GLP-1 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oral GLP-1 麻豆原创 Size (2018-2029)
7.2 Europe Oral GLP-1 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Oral GLP-1 麻豆原创 Size by Country (2018-2023)
7.4 Europe Oral GLP-1 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oral GLP-1 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Oral GLP-1 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Oral GLP-1 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Oral GLP-1 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oral GLP-1 麻豆原创 Size (2018-2029)
9.2 Latin America Oral GLP-1 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Oral GLP-1 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Oral GLP-1 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oral GLP-1 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Oral GLP-1 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Oral GLP-1 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Oral GLP-1 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Oral GLP-1 Introduction
11.1.4 Eli Lilly Revenue in Oral GLP-1 Business (2018-2023)
11.1.5 Eli Lilly Recent Development
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Detail
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk Oral GLP-1 Introduction
11.2.4 Novo Nordisk Revenue in Oral GLP-1 Business (2018-2023)
11.2.5 Novo Nordisk Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Oral GLP-1 Introduction
11.3.4 Pfizer Revenue in Oral GLP-1 Business (2018-2023)
11.3.5 Pfizer Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Oral GLP-1 Introduction
11.4.4 AstraZeneca Revenue in Oral GLP-1 Business (2018-2023)
11.4.5 AstraZeneca Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Oral GLP-1 Introduction
11.5.4 Sanofi Revenue in Oral GLP-1 Business (2018-2023)
11.5.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Eli Lilly
Novo Nordisk
Pfizer
AstraZeneca
Sanofi

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.